Literature DB >> 21264910

Pre-eminence and persistence of immature natural killer cells in acute myeloid leukemia patients in first complete remission.

Nicolas Dauguet1, Christian Récher, Cécile Demur, Jean-Jacques Fournié, Mary Poupot, Rémy Poupot.   

Abstract

Despite substantial progress in the treatment of AML, a proportion of patients do not achieve first complete remission (1(st) CR) with the induction chemotherapy, and, among patients achieving it, a majority is expected to relapse within three years. As allogeneic hematopoietic stem cell transplantation has been established as the most effective form of antileukemic therapy in patients with AML in remission, many studies have focused on the reconstitution and the functionality of the innate immune system in this context, especially regarding cytotoxic effectors such as natural killer (NK) cells. On the contrary, very few data are available concerning the innate immune system of patients in 1st CR. Herein we investigated the phenotype of autologous NK cells of AML patients in 1st CR. We showed that immature NK cells were pre-eminent in the blood of these patients and that this immature phenotype was persistent during the first months after 1st CR.
Copyright © 2010 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21264910     DOI: 10.1002/ajh.21906

Source DB:  PubMed          Journal:  Am J Hematol        ISSN: 0361-8609            Impact factor:   10.047


  11 in total

Review 1.  Regulatory T cells in acute myelogenous leukemia: is it time for immunomodulation?

Authors:  Celalettin Ustun; Jeffrey S Miller; David H Munn; Daniel J Weisdorf; Bruce R Blazar
Journal:  Blood       Date:  2011-08-31       Impact factor: 22.113

Review 2.  NK cells: key to success of DC-based cancer vaccines?

Authors:  Eva Lion; Evelien L J M Smits; Zwi N Berneman; Viggo F I Van Tendeloo
Journal:  Oncologist       Date:  2012-08-20

3.  MicroRNA-29b mediates altered innate immune development in acute leukemia.

Authors:  Bethany L Mundy-Bosse; Steven D Scoville; Li Chen; Kathleen McConnell; Hsiaoyin C Mao; Elshafa H Ahmed; Nicholas Zorko; Sophia Harvey; Jordan Cole; Xiaoli Zhang; Stefan Costinean; Carlo M Croce; Karilyn Larkin; John C Byrd; Sumithira Vasu; William Blum; Jianhua Yu; Aharon G Freud; Michael A Caligiuri
Journal:  J Clin Invest       Date:  2016-10-24       Impact factor: 14.808

4.  Targeting of acute myeloid leukemia in vitro and in vivo with an anti-CD123 mAb engineered for optimal ADCC.

Authors:  S J Busfield; M Biondo; M Wong; H S Ramshaw; E M Lee; S Ghosh; H Braley; C Panousis; A W Roberts; S Z He; D Thomas; L Fabri; G Vairo; R B Lock; A F Lopez; A D Nash
Journal:  Leukemia       Date:  2014-04-07       Impact factor: 11.528

5.  Kinetics of Cytotoxic Lymphocytes Reconstitution after Induction Chemotherapy in Elderly AML Patients Reveals Progressive Recovery of Normal Phenotypic and Functional Features in NK Cells.

Authors:  Jérôme Rey; Cyril Fauriat; Eloïse Kochbati; Florence Orlanducci; Aude Charbonnier; Evelyne D'Incan; Pascale Andre; François Romagne; Bernadette Barbarat; Norbert Vey; Daniel Olive
Journal:  Front Immunol       Date:  2017-02-02       Impact factor: 7.561

6.  CD123 target validation and preclinical evaluation of ADCC activity of anti-CD123 antibody CSL362 in combination with NKs from AML patients in remission.

Authors:  L H Xie; M Biondo; S J Busfield; A Arruda; X Yang; G Vairo; M D Minden
Journal:  Blood Cancer J       Date:  2017-06-02       Impact factor: 11.037

7.  Impact of microRNA-29b on natural killer cells in T-cell acute lymphoblastic leukemia.

Authors:  Fengyan Jin; Zhonghua Du; Yang Tang; Lixia Wang; Yanping Yang
Journal:  Oncol Lett       Date:  2019-07-04       Impact factor: 2.967

Review 8.  Natural Killer Cells in Myeloid Malignancies: Immune Surveillance, NK Cell Dysfunction, and Pharmacological Opportunities to Bolster the Endogenous NK Cells.

Authors:  Mattias Carlsten; Marcus Järås
Journal:  Front Immunol       Date:  2019-10-11       Impact factor: 7.561

Review 9.  Natural killer cell-based immunotherapy for acute myeloid leukemia.

Authors:  Jing Xu; Ting Niu
Journal:  J Hematol Oncol       Date:  2020-12-07       Impact factor: 17.388

10.  Role of natural killer cell subsets and natural cytotoxicity receptors for the outcome of immunotherapy in acute myeloid leukemia.

Authors:  Anna Martner; Anna Rydström; Rebecca E Riise; Johan Aurelius; Harald Anderson; Mats Brune; Robin Foà; Kristoffer Hellstrand; Fredrik B Thorén
Journal:  Oncoimmunology       Date:  2015-05-05       Impact factor: 8.110

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.